The Role of Thiopurines in Pediatric Inflammatory Bowel Diseases: A Real-Life Prospective Cohort Study.
Use of thiopurines for inflammatory bowel diseases (IBD) is declining in some parts of the world. We aimed to explore outcomes of thiopurines and predictors of response in a real-world prospective cohort of children with dose optimization. Children with IBD treated with thiopurines without biologics were enrolled. Dosing was guided by TPMT-activity at baseline and by clinical response and toxicity at 4 months; one year into the study, therapeutic-drug-monitoring (TDM) at 4 months was also considered in the decision making. The primary outcome was steroid-free remission without treatment escalation by 12 month (SFR), utilizing the intention-to-treat approach. A total of 129 children were included (74% Crohn's disease (CD) and 26% ulcerative colitis (UC)). SFR was achieved in 37 (39%) CD and 13 (39%) UC patients, and SFR with normal ESR/CRP in 20 (21%) and 9 (27%), respectively. At 4 months, MCV/WBC ratio and ΔANC weakly correlated with 6-thioguanine (r = 0.33, p = 0.02 and r = 0.32, p = 0.02, respectively). In CD, SFR was associated with 4-month median wPCDAI (2.5 (IQR 0-7.5) in responders vs 5 in non-responders (0-12.5), p = 0.048) and ΔANC (1.7 (IQR 0.7-4.1) vs 0.05 (-2.3-0.9); p = 0.03). Mild drug-related adverse events were recorded in 30 children (22%), 3 required stopping the drug. In this real-life prospective cohort utilizing dose optimization, thiopurines were safe and effective in 21% of CD and 27% of UC patients, including normalization of CRP and ESR. Thiopurines remain a viable option in the treatment algorithm of mild-moderate paediatric IBD, especially in females whose risk for lymphoma is lower.